Pure Global

Wuding four-in-one multi-function analyzer - Taiwan Registration 7f74e390f54633c09a6c7783ac084c3c

Access comprehensive regulatory information for Wuding four-in-one multi-function analyzer in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 7f74e390f54633c09a6c7783ac084c3c and manufactured by APEX BIOTECHNOLOGY CORPORATION. The authorized representative in Taiwan is APEX BIOTECHNOLOGY CORPORATION.

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
89,000+ Devices
7f74e390f54633c09a6c7783ac084c3c
Registration Details
Taiwan FDA Registration: 7f74e390f54633c09a6c7783ac084c3c
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

Wuding four-in-one multi-function analyzer
TW: ไบ”้ผŽๅ››ๅˆไธ€ๅคšๅŠŸ่ƒฝๅˆ†ๆžๅ„€
Risk Class 2

Registration Details

7f74e390f54633c09a6c7783ac084c3c

Company Information

Taiwan, Province of China

Product Details

This product is used with Wuding glycosylated hemoglobin reagent cartridge to quantitatively detect the concentration of glycosylated hemoglobin in fingertip microvascular whole blood or venous whole blood, and with Wuding microalbumin reagent cartridge, creatinine reagent cartridge and microalbumin/creatinine ratio reagent cartridge, the concentration of trace albumin, creatinine and urine microalbumin/creatinine ratio ratio in urine is quantitatively detected.

B Hematology, Pathology and Genetics;; A Clinical Chemistry and Clinical Toxicology;; C Immunology and Microbiology

C.5040 ็™ฝ่›‹็™ฝๅ…็–ซ่ฉฆ้ฉ—็ณป็ตฑ;; A.1225 ่‚Œๆฐจ้…ธ้…่ฉฆ้ฉ—็ณป็ตฑ(Creatininetestsystem);; B.7470 ็ณ–(ๅŸบ)ๅŒ–่ก€็ด…็ด ๅˆ†ๆž

QMS/QSD;; ๅœ‹็”ข

Dates and Status

Nov 02, 2023

Nov 02, 2028